The Wayback Machine - https://web.archive.org/web/20111115222745/http://en.wikipedia.org/wiki/Levomilnacipran

Levomilnacipran

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Levomilnacipran
Systematic (IUPAC) name
(1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenylcyclopropanecarboxamide
Clinical data
Pregnancy cat.  ?
Legal status Non-regulated
Routes Oral
Identifiers
CAS number 96847-55-1 YesY
175131-60-9 (hydrochloride)
ATC code None
PubChem CID 65833
UNII UGM0326TXX YesY
Chemical data
Formula C15H22N2O 
Mol. mass 246.348 g/mol
 YesY(what is this?)  (verify)

Levomilnacipran (F2695) is an antidepressant currently under development by Forest Laboratories for the treatment of depression in the United States and Canada.[1][2][3] As of 2009 it is in phase III clinical trials.[4] Levomilnacipran is an active enantiomer of milnacipran and therefore has similar effects and pharmacology, acting as a serotonin-norepinephrine reuptake inhibitor.[2][5] On 20 January 2011, Forest and Pierre Fabre Medicament announced that levomilnacipran was no better than placebo in a late-stage clinical trial. Two other late-stage trials will be finished in mid-2011.

[edit] See also

[edit] References

  1. ^ "Future Treatments for Depression, Anxiety, Sleep Disorders, Psychosis, and ADHD -- Neurotransmitter.net". http://www.neurotransmitter.net/newdrugs.html. 
  2. ^ a b "Pierre Fabre Medicament and Forest Laboratories to Collaborate on Development and Commercialization of F2695 for Depression - FierceBiotech". http://www.fiercebiotech.com/press-releases/pierre-fabre-medicament-and-forest-laboratories-collaborate-development-and-commerc-0. 
  3. ^ "Search of: F2695 - List Results - ClinicalTrials.gov". http://clinicaltrials.gov/ct2/results?term=F2695. 
  4. ^ Deprez D, Chassard D, Baille P, Mignot A, Ung HL, Puozzo C (1998). "Which bioequivalence study for a racemic drug? Application to milnacipran". European Journal of Drug Metabolism and Pharmacokinetics 23 (2): 166–71. PMID 9725476. 


v · d · eAnxiolytics (N05B)
GABAA PAMs
Others
α2δ VDCC Blockers
5-HT1A Agonists
Azapirones: Buspirone • Gepirone • Tandospirone; Others: Flesinoxan • Oxaflozane
H1 Antagonists
Diphenylmethanes: Captodiame • Hydroxyzine; Others: Brompheniramine • Chlorpheniramine • Pheniramine
CRH1 Antagonists
NK2 Antagonists
MCH1 antagonists
mGluR2/3 Agonists
mGluR5 NAMs
TSPO agonists
σ1 agonists
Others
#WHO-EM. ‡Withdrawn from market. Clinical trials: †Phase III. §Never to phase III

M: PSO/PSI

dsrd (o, p, m, p, a, d, s), sysi/epon, spvo

proc(eval/thrp), drug(N5A/5B/5C/6A/6B/6D)
Stub icon This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.
Retrieved from "http://en.wikipedia.org/w/index.php?title=Levomilnacipran&oldid=457398621"
Personal tools
Namespaces
Variants
Actions
Navigation
Interaction
Toolbox
Print/export
Morty Proxy This is a proxified and sanitized view of the page, visit original site.